Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.37 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.36 |
| ▸ | FOS | P01100 | 1/20 | 0.36 |
| ▸ | TTR | P02766 | 1/20 | 0.36 |
| ▸ | JUN | P05412 | 1/20 | 0.36 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.36 |
| ▸ | HSD17B1 | P14061 | 1/20 | 0.36 |
| ▸ | HSD17B2 | P37059 | 1/20 | 0.36 |
| ▸ | CA2 | P00918 | 3/20 | 0.35 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.35 |
| ▸ | HTR2A | P28223 | 3/20 | 0.35 |
| ▸ | TAAR1 | Q96RJ0 | 2/20 | 0.35 |
| ▸ | CA1 | P00915 | 2/20 | 0.34 |
| ▸ | CA4 | P22748 | 2/20 | 0.34 |
| ▸ | CA6 | P23280 | 2/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3043068 | 0.86 | CA2 (0.35) | MAPTNPSR1FOSTTRJUN | |
| SCHEMBL27650457 | 0.82 | PTGS2 (0.55) | MAPTPTGS2HTR2A | |
| SCHEMBL3044667 | 0.82 | LMNA (0.40) | FOSTTRJUNNR3C1HSD17B1 | |
| SCHEMBL3036388 | 0.80 | ALDH1A1 (0.34) | FOSTTRJUNNR3C1HSD17B1 | |
| SCHEMBL3037185 | 0.79 | PTGS2 (0.40) | MAPTNPSR1PTPN1CA2PTGS2 | |
| SCHEMBL24703587 | 0.79 | SRC (0.43) | MAPTPTGS2HTR2A | |
| SCHEMBL19129605 | 0.77 | CA2 (0.59) | CA2 | |
| SCHEMBL12712736 | 0.77 | FOS (0.37) | PTPN1FOSTTRJUNNR3C1 | |
| SCHEMBL31063263 | 0.77 | MAPT (0.49) | MAPT | |
| SCHEMBL4964961 | 0.76 | PTPN1 (0.34) | PTPN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8530504-B2 | Pyrazolothiazole compound | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2013-09-10 | — | — | US | disclosed |
| US-8530504-B2 | Pyrazolothiazole compound | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2013-09-10 | — | — | US | disclosed |
| US-8530504-B2 | Pyrazolothiazole compound | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2013-09-10 | — | — | US | disclosed |
| EP-2487178-A1 | PYRAZOLOTHIAZOLE COMPOUND | Eisai R&D Management Co., Ltd. (JP) | 2012-08-15 | — | — | EP | disclosed |
| US-20110086882-A1 | PYRAZOLOTHIAZOLE COMPOUND | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2011-04-14 | — | — | US | disclosed |
| US-20110086882-A1 | PYRAZOLOTHIAZOLE COMPOUND | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2011-04-14 | — | — | US | disclosed |
| US-20110086882-A1 | PYRAZOLOTHIAZOLE COMPOUND | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2011-04-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110086882-A1 | PYRAZOLOTHIAZOLE COMPOUND | CRHR1, CNR1, AGTR1 | MAPT 4509/4885NPSR1 5/4885PTPN1 620/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.